FLGT - Fulgent Genetics Inc Forecast, Target Price
This article provides a detailed financial overview and forecast for Fulgent Genetics Inc (FLGT). It includes key metrics such as market capitalization, income, sales, earnings per share, and stock performance indicators. The report also highlights analyst recommendations and a target price for the company's stock.
Enterprise value to EBITDA forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
This article provides access to the enterprise value to EBITDA forward data for Fulgent Genetics, Inc. (NASDAQ: FLGT) via the TradingView platform. It navigates through the financial metrics available for the company within the health services sector. The content primarily focuses on directing users to financial data rather
Price to earnings forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
This article displays financial information for Fulgent Genetics, Inc. (NASDAQ: FLGT), focusing on its forward price-to-earnings ratio. The content is presented on a financial data platform, providing a snapshot of the company's valuation metric. It confirms that the market was closed at the time of viewing with no trades.
Enterprise value to EBIT forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
This article presents financial information for Fulgent Genetics, Inc. (NASDAQ:FLGT), focusing on its enterprise value to EBIT forward metric. It appears to be a stub or preview from a financial data platform, providing a title but no detailed content beyond company identification and a mention of market data providers.
Enterprise value to EBIT forward of Fulgent Genetics, Inc. – BMV:FLGT
This article focuses on the enterprise value to EBIT forward metric for Fulgent Genetics, Inc. (BMV:FLGT). The content appears to be a financial data page from TradingView, offering an overview of the company's financial performance. It provides no analytical text but lists the metric's value and change, indicating it is a data point for financial analysis.
Price to sales forward of Fulgent Genetics, Inc. – BMV:FLGT
The article provides financial information for Fulgent Genetics, Inc. (BMV:FLGT), specifically focusing on its price-to-sales forward ratio. It seems to be a financial data snippet from TradingView, indicating the market status and offering various tools and resources related to financial analysis.
Enterprise value to revenue forward of Fulgent Genetics, Inc. – NASDAQ:FLGT
The article focuses on the enterprise value to revenue forward metric for Fulgent Genetics, Inc. (NASDAQ:FLGT). It appears to be a financial data snippet or a specific analytical view provided by TradingView, detailing a specific metric for the company.
Price to earnings forward of Fulgent Genetics, Inc. – BMV:FLGT
This article provides the "Price to earnings forward" metric for Fulgent Genetics, Inc. (BMV:FLGT). It indicates that the market was closed with no trades when the information was accessed. The content is presented within the context of TradingView's financial data platform.
Fulgent Genetics, Inc. Actuals & Estimates (NASDAQ:FLGT)
This article provides comprehensive financial data and analyst estimates for Fulgent Genetics, Inc. (NASDAQ: FLGT), covering income statements, balance sheets, cash flow, and valuation metrics. It highlights the stock's recent performance, including a 0.82% increase in the last 24 hours, and presents a uniform analyst price target of $15.00. The company's next earnings report is scheduled for July 31, 2026, with recent earnings showing a slight surprise.
How (FLGT) Movements Inform Risk Allocation Models
This article analyzes Fulgent Genetics Inc. (FLGT) using AI models to inform risk allocation. It highlights a positive near-term sentiment with potential for a broader shift, identifying specific support and resistance levels. The piece also outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—all with sophisticated risk management parameters.
FLGT Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Fulgent Genetics, Inc. (FLGT). It includes analyst ratings, historical stock performance, key financial metrics, and upcoming earnings dates. The current stock price is $19.44, with analysts' maximum and minimum price targets set at $15.00.
Fulgent Genetics (FLGT) Stock Faces Mixed Analyst Target Changes After Margin Questions
Analysts are maintaining Fulgent Genetics' (FLGT) fair value at US$15.00, indicating that core valuation frameworks remain stable despite recent changes in expectations around execution risk. While some analysts remain bullish due to intact business model assumptions, Piper Sandler downgraded its price target, signaling caution regarding near-term execution, commercialization, and cost structure. The article suggests investors monitor the evolving narrative, clinical news, and broader market developments for Fulgent Genetics.
Fulgent Genetics Inc (FLGT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Fulgent Genetics Inc (FLGT), noting its current valuation score of 9.04 and ranking within the Healthcare Providers & Services industry. It highlights the company's P/E ratio, comparing it to recent highs and lows, and indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company. The report reflects data as of June 23, 2026.
Fulgent Genetics Inc (FLGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Fulgent Genetics Inc (FLGT), detailing its current price momentum score, support and resistance levels, and indicator readings. It presents a summary of various technical indicators like MACD, RSI, and moving averages (MA5 to MA200), offering a combined signal of "Sell". The analysis aims to help traders identify potential trends and make informed decisions, though it emphasizes that technical analysis is for reference only and not an absolute standard.
Fulgent Genetics Inc (FLGT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Fulgent Genetics Inc (FLGT), highlighting its current earnings forecast score, average price target of $35.00, and analyst rating as "Hold." It also gives details on expected revenue, EPS for the next quarter, and peer comparisons within the Healthcare Providers & Services industry. The financial data is provided by LSEG and emphasizes that the information is for informational purposes only.
Fulgent Genetics Inc (FLGT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Fulgent Genetics Inc (FLGT) including its current stock price, market capitalization, and financial performance metrics. It specifically highlights that the company has not distributed any dividends over the past five years and lists that there is no historical data available for stock splits.
Fulgent Genetics Inc (FLGT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Fulgent Genetics Inc (FLGT), listing major individual and institutional holders and their respective proportions. It also presents institutional shareholding trends over several quarters and shows the company's inclusion in various ETFs. The data highlights key investors like Hsieh (Ming) and BlackRock Institutional Trust Company.
Fulgent Genetics Inc (FLGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Fulgent Genetics Inc (FLGT), categorized by business segments and geographic regions. For FY2023, the company's revenue distribution shows that the institutional segment contributes the most, followed by insurance and patient services. Regionally, the United States accounts for the vast majority of its revenue.
Fulgent Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) and reminds investors of the November 21, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Fulgent engaged in medically unnecessary laboratory testing and improper billing practices, leading to an SEC investigation and a drop in stock price. Investors who suffered losses exceeding $100,000 are encouraged to contact Faruqi & Faruqi to discuss their legal options.
FLGT - Fulgent Genetics Inc Stock Price and Quote
This article provides a detailed financial overview and news compilation for Fulgent Genetics Inc (FLGT). It includes the latest stock close, market capitalization, key financial ratios, insider transaction details, and a chronological list of recent news and analyst ratings. The data suggests an active period for the company, with several earnings reports, acquisitions, and presentations on oncology candidates.
How Fulgent Genetics Inc. (FLGT) Affects Rotational Strategy Timing
Fulgent Genetics Inc. (FLGT) is showing strong near and mid-term sentiment but a weak long-term outlook, with an exceptional risk-reward short setup targeting a significant downside. AI models have generated distinct trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. The analysis indicates a mid-channel oscillation pattern and highlights current signals for positioning and risk parameters.
Fulgent Genetics CSO Gao Hanlin sells $30,190 in stock
Fulgent Genetics Chief Scientific Officer Gao Hanlin sold 1,688 shares of company stock worth $30,190 to cover tax withholding obligations. Following the sale, Hanlin still holds 990,374 shares. The company recently reported lower-than-expected Q1 2026 earnings and revenue but holds more cash than debt and is developing new services like FoundationOne PGx and advancing a Phase 2 clinical trial for a cancer drug.
Fulgent Genetics (NASDAQ: FLGT) insider sale covers RSU taxes
Fulgent Genetics President and COO Jian Xie sold 2,146 shares of common stock on June 2, 2026, at a weighted-average price of $17.8855 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units granted in February 2025. Following the transaction, Xie directly holds 367,605 shares and indirectly holds an additional 220,816 shares through The Hsieh Family Dynasty Trust.
Fulgent Genetics (FLGT) CSO sells 1,688 shares to cover RSU tax
Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 1,688 shares of common stock at a weighted-average price of $17.8855 per share. This sale was conducted to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Gao directly holds 990,374 shares of Fulgent Genetics common stock.
Fulgent Genetics (FLGT) CFO reports tax withholding of vested RSU shares
Fulgent Genetics (FLGT) CFO Paul Kim reported a routine share disposition where 2,087 shares of common stock were withheld at $18.09 per share to cover tax obligations from the vesting of restricted stock units. This was a non-market event related to compensation, not an open-market sale. After this transaction, Kim directly holds 362,545 shares of Fulgent Genetics common stock.
Fulgent Genetics (NASDAQ: FLGT) Form 144 lists 45,304 vested shares; small prior sale
Fulgent Genetics (NASDAQ: FLGT) filed a Form 144 indicating the intended resale of 45,304 restricted common shares that vested on February 25, 2025. The filing also disclosed a prior sale of 1,201 shares on May 27, 2026, by Jian Xie, with Morgan Stanley Smith Barney LLC listed as the broker. This administrative filing provides procedural disclosures required for restricted stock sales.
Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR
Fulgent presented updated preliminary Phase 2 data at ASCO for its drug FID-007 combined with cetuximab for R/M HNSCC, showing a 61.9% objective response rate. The data also indicated a median PFS of 6.7 months and a one-year overall survival of 63.4%, with activity observed in both HPV-related and unrelated HNSCC. The company plans to proceed with a Phase 3 study for this drug combination.
Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulgent Genetics (NASDAQ: FLGT) announced updated data from its FID-007 clinical trial for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) at the ASCO 2026 Annual Meeting. The trial showed a 61.9% objective response rate, median progression-free survival of 6.7 months, and 7.4 months median duration of response when FID-007 was used in combination with cetuximab. These positive results indicate a manageable safety profile and clinical activity in patients whose disease progressed after PD-1 based therapy, leading to plans for a Phase 3 study.
Strong FID-007 Phase 2 results for Fulgent Genetics (NASDAQ: FLGT)
Fulgent Genetics announced promising preliminary Phase 2 results for its cancer drug candidate FID-007, presented at the ASCO 2026 Annual Meeting. The study, evaluating FID-007 combined with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma, showed significant clinical activity and a manageable safety profile. The company plans a Phase 3 study for FID-007 following these encouraging outcomes.
Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulgent Genetics presented updated preliminary data for its FID-007 drug in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma at the ASCO 2026 Annual Meeting. The data showed promising clinical activity and a manageable safety profile, with an objective response rate of 61.9% and a one-year overall survival of 63.4%. These positive results support the company's plan to proceed with a Phase 3 study.
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding
Jian Xie, President and COO of Fulgent Genetics (NASDAQ: FLGT), sold 1,201 shares of common stock on May 27, 2026, at a weighted-average price of $17.60 per share. This sale was conducted to cover tax withholding obligations stemming from the vesting of restricted stock units granted in February 2024. Following the transaction, Xie directly holds 369,751 shares, with an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust.
Fulgent Genetics (FLGT) CSO sells 945 shares to cover tax obligations
Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 945 shares of common stock on May 27, 2026, at a weighted-average price of $17.60 per share. This transaction was conducted to satisfy tax withholding obligations arising from vested restricted stock units. Following the sale, Gao directly holds 992,062 shares, indicating the sale was a small, routine portion of his overall stake.
Fulgent Genetics COO Jian Xie sells $21,137 in company stock
Jian Xie, the President and COO of Fulgent Genetics (NASDAQ:FLGT), sold 1,201 shares of company stock for $21,137 on May 27, 2026, primarily to cover tax obligations from vested restricted stock units. Following this transaction, Xie directly holds 369,751 shares and indirectly holds 220,816 shares through a family trust. The company recently reported mixed Q1 2026 financial results, missing EPS and revenue expectations, but is expanding its offerings with a new pharmacogenetic testing service and progressing in clinical trials for a cancer drug.
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity
Fulgent Genetics, Inc.'s CFO and Treasurer, Paul Kim, reported a disposition of 1,168 common shares on May 26, 2026, to cover tax obligations from vested restricted stock units. Following this transaction, Kim directly holds 364,632 common shares. The filing, a Form 4, details the tax withholding at a price of $17.67 per share.
Ming Hsieh (FLGT) reports 32% Fulgent Genetics stake and major share pledges
Fulgent Genetics CEO Ming Hsieh has filed an amendment updating his beneficial ownership in the company to 32.26%, totaling 8,872,539 shares. This includes shares held by The Ming Hsieh Trust, which also has significant shares pledged under a pre-paid forward arrangement and as collateral for a credit facility, meaning a lender could dispose of them in case of default. Hsieh acquired additional shares through equity award vestings and states his stake is for general investment purposes, with potential increases or decreases in the future.
Fulgent Genetics (FLGT) CEO reports RSU tax withholding and large trust holdings
Fulgent Genetics CEO Ming Hsieh reported a routine tax withholding of 2,949 shares of common stock at $17.67 per share to cover tax obligations arising from the vesting of restricted stock units. Following this, he directly holds 897,685 shares, and substantial indirect holdings are maintained through various trusts, including The Ming Hsieh Trust and the Dynasty Trust. The report clarifies this event as a standard tax-related transaction, not an open-market sale.
(FLGT) and the Role of Price-Sensitive Allocations
This article provides an analysis of Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It details various AI-generated trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis for support and resistance levels. The report also emphasizes an exceptional risk-reward setup targeting a 37.0% gain.
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics
Lowey Dannenberg, P.C. is investigating Fulgent Genetics, Inc. (NASDAQ: FLGT) for potential violations of federal securities laws. This investigation follows Fulgent's report of fourth-quarter revenue decline and full-year 2025 revenue that fell short of updated guidance. The firm encourages investors who suffered losses to contact their attorneys.
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Genetics (NASDAQ: FLGT) announced the publication of its full abstract for FID-007, to be presented at the ASCO 2026 Annual Meeting's Head and Neck Cancer Track. The abstract details interim data from a Phase 2 study evaluating FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Results show meaningful clinical activity and a favorable safety profile, with an objective response rate of 60% and median progression-free survival of 7.2 months.
Fulgent Announces ASCO Rapid Oral Abstract Showing 60% ORR, 7.2‑mo mPFS for FID-007 plus Cetuximab
Fulgent (FLGT) reported positive interim Phase 2 data for its drug FID-007 combined with cetuximab, showing a 60% objective response rate and a median progression-free survival of 7.2 months. These findings will be presented at the ASCO Rapid Oral session on June 1, 2026. The company noted a favorable safety profile with mostly grade 1–2 treatment-related adverse events.
Fulgent (NASDAQ: FLGT) reports 60% ORR in Phase 2 FID-007 cancer trial
Fulgent Genetics announced positive interim Phase 2 results for its cancer drug candidate FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The study showed an objective response rate of 60% and a median progression-free survival of 7.2 months in 42 efficacy-evaluable patients. The company highlights these results as significantly better than historical standards of care, with a favorable safety profile noted, although overall survival data is still immature.
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Genetics, Inc. announced the full abstract publication for its drug FID-007, which will be presented at the ASCO 2026 Annual Meeting in the Head and Neck Cancer Track. Interim Phase 2 study data show FID-007, combined with cetuximab, demonstrates meaningful clinical activity and a favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with an objective response rate of 60%. This new treatment option shows potential for a patient population where current therapies have limited efficacy.
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
Fulgent Genetics (NASDAQ: FLGT) announced that its full abstract for FID-007 has been published for the ASCO 2026 Annual Meeting, detailing interim data from its Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The study showed meaningful clinical activity and a favorable safety profile for FID-007 in combination with cetuximab, achieving an objective response rate of 60% and a median progression-free survival of 7.2 months. These results highlight FID-007's potential as a treatment for R/M HNSCC, offering significant improvement over current standard-of-care options.
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT) following a reported decline in revenue and a significant impact from a transitioning major customer. The firm is focusing on whether Fulgent's executive officers complied with federal securities laws and is encouraging affected shareholders to join their investigation to potentially recover losses.
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT) to determine if investor losses can be recovered under federal securities laws. The investigation follows Fulgent's disclosure of lower-than-anticipated 2025 revenue and decreased fourth-quarter revenue, primarily due to reduced volume from its largest customer transitioning testing in-house. Shareholders who suffered losses are encouraged to contact Johnson Fistel for more information.
FLGT Stock Chart | FULGENT GENETICS INC (NASDAQ:FLGT)
This page provides a stock chart for FULGENT GENETICS INC (NASDAQ:FLGT), displaying its current stock price and key financial details. It offers various chart views (daily, weekly, monthly, candles, bar, line) and links to other sections like technical analysis, fundamental analysis, and news. The article also lists pre-market and after-hours trading data.
Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant
Fulgent Genetics director Michael Nohaile reported new equity awards, including 5,558 shares of common stock and options for 8,426 shares with an exercise price of $16.19. Both the restricted stock units and options vest over a four-year period, contingent on his continued service to the company. These awards are compensation-related grants, not open-market transactions, and bring Nohaile's direct holdings to 24,578 shares.
Fulgent Genetics (NASDAQ: FLGT) director awarded 11,117 restricted stock units
Fulgent Genetics director Regina E. Groves was granted 11,117 restricted stock units (RSUs) of common stock, increasing her direct holdings to 28,099 shares. These RSUs were awarded at no cash cost and will vest over a four-year period, with the first quarter vesting after 12 months and the rest quarterly over the subsequent 36 months, conditional on her continued service. The transaction was reported via a Form 4 filing with the SEC.
Fulgent Genetics (NASDAQ: FLGT) director receives 11,117 RSUs
Fulgent Genetics (NASDAQ: FLGT) director Linda Dong was granted 11,117 Restricted Stock Units (RSUs) with a grant price of $0.00, increasing her direct holdings to 38,758 shares. These RSUs will vest over four years, with a quarter vesting after 12 months (May 14, 2026) and the remainder quarterly over the next three years, contingent on her continued service. The transaction was reported in a Form 4 filing and is considered compensation rather than an open-market purchase.
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87
This article reports a significant decrease in the price target for Fulgent Genetics (FLGT). The target has been lowered by 28.85% to $18.87. Further details regarding the reasons for this adjustment are not provided in the snippet.
